Newsbenzinga
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
· Published
Article summary
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
An excerpt from the original article.
Comments —
Loading comments…